Lumexa Imaging (NASDAQ:LMRI) Posts Quarterly Earnings Results

Lumexa Imaging (NASDAQ:LMRI) released its quarterly earnings data on Wednesday. The company reported $0.20 EPS for the quarter, FiscalAI reports. The business had revenue of $264.16 million during the quarter.

Lumexa Imaging Stock Performance

LMRI stock traded up $0.07 on Wednesday, hitting $11.73. The company’s stock had a trading volume of 723,479 shares, compared to its average volume of 788,641. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.43. The stock has a market cap of $1.13 billion and a price-to-earnings ratio of -19.88. The firm has a 50 day moving average of $10.62 and a two-hundred day moving average of $10.94.

Insider Buying and Selling

In other Lumexa Imaging news, Director Brett Brodnax bought 35,000 shares of Lumexa Imaging stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average cost of $7.25 per share, with a total value of $253,750.00. Following the completion of the acquisition, the director owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This represents a 129.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Institutional Trading of Lumexa Imaging

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. purchased a new stake in shares of Lumexa Imaging during the fourth quarter worth approximately $36,000. Strs Ohio purchased a new position in Lumexa Imaging in the 1st quarter valued at $38,000. Barclays PLC acquired a new position in Lumexa Imaging in the 4th quarter valued at $133,000. PNC Financial Services Group Inc. purchased a new position in Lumexa Imaging during the 1st quarter worth $63,000. Finally, Sandia Investment Management LP purchased a new position in Lumexa Imaging during the 4th quarter worth $185,000.

Analyst Ratings Changes

LMRI has been the topic of a number of research analyst reports. Barclays cut their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a report on Wednesday, May 20th. Wall Street Zen downgraded shares of Lumexa Imaging from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings raised Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).